NCT06835400View on ClinicalTrials.gov

Oral Paclitaxel + Encequidar vs IV Paclitaxel in Treatment of HER2 Negative Metastatic Breast Cancer

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

340

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

April 30, 2028

Study Completion Date

May 31, 2029

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Paclitaxel Capsule

Paclitaxel Capsule

DRUG

IV Paclitaxel

IV Paclitaxel

DRUG

Encequidar tablet

Encequidar tablet

Sponsors

Lead Sponsor

Health Hope Pharma
All Listed Sponsors
lead

Health Hope Pharma

INDUSTRY